Amgen reported its third-quarter 2024 financial results, showing a notable increase in both revenue and earnings per share (EPS). The company's total revenues for the quarter rose by 23% to $8.5 billion compared to the same period in 2023. The GAAP EPS saw a significant increase of 62%, rising from $3.22 to $5.22, largely driven by mark-to-market gains on its BeiGene equity investment. Additionally, Amgen's adjusted EPS for the quarter was $5.58, surpassing the consensus forecast of $5.11. However, the revenue of $8.5 billion fell slightly below the forecast of $8.52 billion. The company also narrowed its full-year 2024 adjusted EPS guidance to a range of $19.20 to $20.00, and its revenue guidance to a range of $33 billion to $33.8 billion. Amgen's market cap stands at $169.75 billion.